

Alexander C. Ford

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/656134/alexander-c-ford-publications-by-year.pdf>

Version: 2024-04-09

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

466 papers	20,268 citations	76 h-index	134 g-index
547 ext. papers	25,427 ext. citations	8.1 avg, IF	7.62 L-index

#	Paper	IF	Citations
466	Efficacy of eradication therapy for functional dyspepsia: updated systematic review and meta-analysis.. <i>Gut</i> , 2022 ,	19.2	4
465	A specific microbiota signature is associated to various degrees of ulcerative colitis as assessed by a machine learning approach.. <i>Gut Microbes</i> , 2022 , 14, 2028366	8.8	1
464	Letter in response to Black et al. (2020): Authors' Reply.. <i>Neurogastroenterology and Motility</i> , 2022 , e14388		
463	Latent class analysis does not support the existence of Rome IV functional bowel disorders as discrete entities.. <i>Neurogastroenterology and Motility</i> , 2022 , e14391	4	0
462	Longitudinal follow-up of a novel classification system for irritable bowel syndrome: natural history and prognostic value. <i>Alimentary Pharmacology and Therapeutics</i> , 2021 , 53, 1126-1137	6.1	4
461	Constipation Predominant Irritable Bowel Syndrome and Functional Constipation Are Not Discrete Disorders: A Machine Learning Approach. <i>American Journal of Gastroenterology</i> , 2021 , 116, 142-151	0.7	4
460	Symptom Stability in Rome IV vs Rome III Irritable Bowel Syndrome. <i>American Journal of Gastroenterology</i> , 2021 , 116, 362-371	0.7	12
459	A Novel Method to Classify and Subgroup Patients With IBS Based on Gastrointestinal Symptoms and Psychological Profiles. <i>American Journal of Gastroenterology</i> , 2021 , 116, 372-381	0.7	11
458	Efficacy of Ondansetron for Irritable Bowel Syndrome With Diarrhea. <i>American Journal of Gastroenterology</i> , 2021 , 116, 428-429	0.7	1
457	Biochemical Tests for Bile Acid Diarrhea: Real-World Studies Required. <i>American Journal of Gastroenterology</i> , 2021 , 116, 833-834	0.7	2
456	Efficacy of Senna and Magnesium Oxide for the Treatment of Chronic Idiopathic Constipation. <i>American Journal of Gastroenterology</i> , 2021 , 116, 1352-1353	0.7	
455	Prognosis of patients with Rome IV-defined versus physician-diagnosed irritable bowel syndrome: Longitudinal follow-up study. <i>Neurogastroenterology and Motility</i> , 2021 , e14282	4	0
454	Association of proton-pump inhibitor use with adverse health outcomes: A systematic umbrella review of meta-analyses of cohort studies and randomised controlled trials. <i>British Journal of Clinical Pharmacology</i> , 2021 ,	3.8	2
453	Adverse events in trials of licensed drugs for irritable bowel syndrome with constipation or diarrhea: Systematic review and meta-analysis. <i>Neurogastroenterology and Motility</i> , 2021 , e14279	4	0
452	Bidirectional brain-gut axis effects influence mood and prognosis in IBD: a systematic review and meta-analysis. <i>Gut</i> , 2021 ,	19.2	4
451	Systematic review and network meta-analysis: efficacy of drugs for functional dyspepsia. <i>Alimentary Pharmacology and Therapeutics</i> , 2021 , 53, 8-21	6.1	18
450	Bugs and the Brain in Inflammatory Bowel Disease: A Novel Treatment Target?. <i>Clinical Gastroenterology and Hepatology</i> , 2021 , 19, 1738-1739	6.9	

449	Impact of Psychological Comorbidity on the Prognosis of Irritable Bowel Syndrome. <i>American Journal of Gastroenterology</i> , 2021 , 116, 1485-1494	0.7	7
448	British Society of Gastroenterology guidelines on the management of irritable bowel syndrome. <i>Gut</i> , 2021 , 70, 1214-1240	19.2	31
447	Overlap of Rome IV Irritable Bowel Syndrome and Functional Dyspepsia and Effect on Natural History: A Longitudinal Follow-Up Study. <i>Clinical Gastroenterology and Hepatology</i> , 2021 ,	6.9	5
446	Common mental disorders in irritable bowel syndrome: pathophysiology, management, and considerations for future randomised controlled trials. <i>The Lancet Gastroenterology and Hepatology</i> , 2021 , 6, 401-410	18.8	7
445	Natural History and Disease Impact of Rome IV Vs Rome III Irritable Bowel Syndrome: A Longitudinal Follow-Up Study. <i>Clinical Gastroenterology and Hepatology</i> , 2021 ,	6.9	5
444	Psychometric evaluation of an experience sampling method-based patient-reported outcome measure in functional dyspepsia. <i>Neurogastroenterology and Motility</i> , 2021 , 33, e14136	4	4
443	Prevalence of symptoms of anxiety and depression in patients with inflammatory bowel disease: a systematic review and meta-analysis. <i>The Lancet Gastroenterology and Hepatology</i> , 2021 , 6, 359-370	18.8	41
442	Healthy Mind, Healthy Body: Chronic Depression May Predate the Development of Inflammatory Bowel Disease by up to 9 Years. <i>Gastroenterology</i> , 2021 , 160, 2611-2613	13.3	0
441	Longitudinal follow-up study: effect of psychological co-morbidity on the prognosis of inflammatory bowel disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2021 , 54, 441-450	6.1	3
440	Irritable bowel syndrome: a spotlight on future research needs. <i>The Lancet Gastroenterology and Hepatology</i> , 2021 , 6, 419-422	18.8	1
439	Systematic review and network meta-analysis: efficacy of licensed drugs for abdominal bloating in irritable bowel syndrome with constipation. <i>Alimentary Pharmacology and Therapeutics</i> , 2021 , 54, 98-108	6.1	4
438	Sarcopenia, severe anxiety and increased C-reactive protein are associated with severe fatigue in patients with inflammatory bowel diseases. <i>Scientific Reports</i> , 2021 , 11, 15251	4.9	0
437	Effect of ACE inhibitors and angiotensin II receptor blockers on disease outcomes in inflammatory bowel disease. <i>Gut</i> , 2021 , 70, 218-219	19.2	3
436	Best management of irritable bowel syndrome. <i>Frontline Gastroenterology</i> , 2021 , 12, 303-315	2.6	5
435	Epidemiology and outcomes of gastroparesis, as documented in general practice records, in the United Kingdom. <i>Gut</i> , 2021 , 70, 644-653	19.2	25
434	Global prevalence of Barrett's oesophagus and oesophageal cancer in individuals with gastro-oesophageal reflux: a systematic review and meta-analysis. <i>Gut</i> , 2021 , 70, 456-463	19.2	17
433	Comparison of the Rome IV criteria with the Rome III criteria for the diagnosis of irritable bowel syndrome in secondary care. <i>Gut</i> , 2021 , 70, 1110-1116	19.2	14
432	Efficacy of surgical or endoscopic treatment of idiopathic achalasia: a systematic review and network meta-analysis. <i>The Lancet Gastroenterology and Hepatology</i> , 2021 , 6, 30-38	18.8	12

431	Ciclosporin or Infliximab as Rescue Therapy in Acute Glucocorticosteroid-Refractory Ulcerative Colitis: Systematic Review and Network Meta-Analysis. <i>Journal of Crohns and Colitis</i> , 2021 , 15, 733-741	1.5	4
430	Chronic constipation in adults: Contemporary perspectives and clinical challenges. 1: Epidemiology, diagnosis, clinical associations, pathophysiology and investigation. <i>Neurogastroenterology and Motility</i> , 2021 , 33, e14050	4	3
429	Efficacy of Oral, Topical, or Combined Oral and Topical 5-Aminosalicylates, in Ulcerative Colitis: Systematic Review and Network Meta-analysis. <i>Journal of Crohns and Colitis</i> , 2021 , 15, 1184-1196	1.5	7
428	In the Face of Adversity: Is Resilience a New Target for Inflammatory Bowel Disease Therapy?. <i>Gastroenterology</i> , 2021 , 160, 466-467	13.3	
427	Chronic constipation in adults: Contemporary perspectives and clinical challenges. 2: Conservative, behavioural, medical and surgical treatment. <i>Neurogastroenterology and Motility</i> , 2021 , 33, e14070	4	2
426	Satiation or satiety? More than mere semantics - Authors' reply. <i>Lancet, The</i> , 2021 , 397, 1061	4.0	
425	A Review of the Evidence and Recommendations on Communication Skills and the Patient-Provider Relationship: AI Rome Foundation Working Team Report. <i>Gastroenterology</i> , 2021 , 161, 1670-1688.e7	13.3	6
424	AGA Clinical Practice Update on Management of Chronic Gastrointestinal Pain in Disorders of Gut-Brain Interaction: Expert Review. <i>Clinical Gastroenterology and Hepatology</i> , 2021 , 19, 2481-2488.e1	6.9	3
423	Reply. <i>Clinical Gastroenterology and Hepatology</i> , 2021 , 19, 1737-1738	6.9	1
422	Efficacy of a low FODMAP diet in irritable bowel syndrome: systematic review and network meta-analysis. <i>Gut</i> , 2021 ,	19.2	12
421	Global prevalence of functional constipation according to the Rome criteria: a systematic review and meta-analysis. <i>The Lancet Gastroenterology and Hepatology</i> , 2021 , 6, 638-648	18.8	15
420	Systematic review with meta-analysis: association of Helicobacter pylori infection with gastro-oesophageal reflux and its complications. <i>Alimentary Pharmacology and Therapeutics</i> , 2021 , 54, 988-998	6.1	0
419	Prevalence of Primary Sclerosing Cholangitis in Patients With Inflammatory Bowel Disease: A Systematic Review and Meta-analysis. <i>Gastroenterology</i> , 2021 , 161, 1865-1877	13.3	2
418	Prevalence and impact of Rome IV versus Rome III irritable bowel syndrome in patients with inflammatory bowel disease. <i>Neurogastroenterology and Motility</i> , 2021 , e14256	4	0
417	The impact of the coronavirus (COVID-19) pandemic on individuals with gastrointestinal disorders: A protocol of an international collaborative study. <i>Journal of Psychosomatic Research</i> , 2021 , 148, 110561	4.1	2
416	Characteristics of, and natural history among, individuals with Rome IV functional bowel disorders. <i>Neurogastroenterology and Motility</i> , 2021 , e14268	4	0
415	Infliximab Therapeutic Drug Monitoring in Inflammatory Bowel Disease Virtual Biologics Clinic Leads to Durable Clinical Results. <i>Inflammatory Intestinal Diseases</i> , 2021 , 6, 132-139	2.5	
414	Systematic review with meta-analysis: risk factors for Barrett's oesophagus in individuals with gastro-oesophageal reflux symptoms. <i>Alimentary Pharmacology and Therapeutics</i> , 2021 , 53, 968-976	6.1	3

413	Efficacy of biological therapies and small molecules in moderate to severe ulcerative colitis: systematic review and network meta-analysis.. <i>Gut</i> , 2021 ,	19.2	5
412	Derivation and validation of a novel method to subgroup patients with functional dyspepsia: beyond upper gastrointestinal symptoms. <i>Alimentary Pharmacology and Therapeutics</i> , 2021 , 53, 253-264	6.1	1
411	Anxiety-related factors associated with symptom severity in irritable bowel syndrome. <i>Neurogastroenterology and Motility</i> , 2020 , 32, e13872	4	20
410	Faecal incontinence is not rare in irritable bowel syndrome. <i>Frontline Gastroenterology</i> , 2020 , 11, 494-496	6.6	1
409	Practical plus personal: a refreshing approach to careers advice by the British Society of Gastroenterology Taster Course. <i>Frontline Gastroenterology</i> , 2020 , 11, 494	2.6	
408	Efficacy of Eluxadoline in Irritable Bowel Syndrome With Diarrhea. <i>American Journal of Gastroenterology</i> , 2020 , 115, 483-484	0.7	2
407	eradication therapy to prevent gastric cancer: systematic review and meta-analysis. <i>Gut</i> , 2020 , 69, 2113-2121	19.2	81
406	Helicobacter pylori eradication for the prevention of gastric neoplasia. <i>The Cochrane Library</i> , 2020 , 7, CD005583	5.2	21
405	Use of Lactulose Breath Tests to Predict Response to Rifaximin in Irritable Bowel Syndrome With Diarrhea: The Positives and Negatives. <i>American Journal of Gastroenterology</i> , 2020 , 115, 955-956	0.7	1
404	Predicting Response to Rifaximin in Irritable Bowel Syndrome with Diarrhea: Is the Answer Blowing in the Wind?. <i>Gastroenterology</i> , 2020 , 158, 1508-1510	13.3	0
403	Polyethylene glycol-based laxatives for chronic constipation - Authors' reply. <i>The Lancet Gastroenterology and Hepatology</i> , 2020 , 5, 110-111	18.8	1
402	Antidepressants in inflammatory bowel disease. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2020 , 17, 184-192	24.2	23
401	Peppermint Oil in Irritable Bowel Syndrome. <i>Gastroenterology</i> , 2020 , 159, 395-396	13.3	5
400	Efficacy of psychological therapies for irritable bowel syndrome: systematic review and network meta-analysis. <i>Gut</i> , 2020 , 69, 1441-1451	19.2	53
399	Overlap Between Irritable Bowel Syndrome and Inflammatory Bowel Disease. <i>Gastroenterology and Hepatology</i> , 2020 , 16, 211-213	0.7	
398	Functional gastrointestinal disorders in inflammatory bowel disease: Time for a paradigm shift?. <i>World Journal of Gastroenterology</i> , 2020 , 26, 3712-3719	5.6	3
397	Efficacy of soluble fibre, antispasmodic drugs, and gut-brain neuromodulators in irritable bowel syndrome: a systematic review and network meta-analysis. <i>The Lancet Gastroenterology and Hepatology</i> , 2020 , 5, 117-131	18.8	58
396	Commentary: estimating the prevalence of IBS globally-past, present and future. <i>Alimentary Pharmacology and Therapeutics</i> , 2020 , 51, 198-199	6.1	4

395	Irritable bowel syndrome. <i>Lancet, The</i> , 2020 , 396, 1675-1688	40	113
394	Functional gastrointestinal disorders: advances in understanding and management. <i>Lancet, The</i> , 2020 , 396, 1664-1674	40	56
393	Functional dyspepsia. <i>Lancet, The</i> , 2020 , 396, 1689-1702	40	83
392	Prevalence of irritable bowel syndrome-type symptoms in patients with inflammatory bowel disease in remission: a systematic review and meta-analysis. <i>The Lancet Gastroenterology and Hepatology</i> , 2020 , 5, 1053-1062	18.8	29
391	Global prevalence of irritable bowel syndrome according to Rome III or IV criteria: a systematic review and meta-analysis. <i>The Lancet Gastroenterology and Hepatology</i> , 2020 , 5, 908-917	18.8	107
390	Systematic review with meta-analysis: global prevalence of uninvestigated dyspepsia according to the Rome criteria. <i>Alimentary Pharmacology and Therapeutics</i> , 2020 , 52, 762-773	6.1	12
389	Letter: faecal microbiota transplantation for irritable bowel syndrome-room for improvement. <i>Alimentary Pharmacology and Therapeutics</i> , 2020 , 52, 923-924	6.1	2
388	Review: Prevention and management of gastric cancer. <i>Helicobacter</i> , 2020 , 25 Suppl 1, e12740	4.9	7
387	Bloating and Abdominal Distention 2020 , 380-385		
386	Rational investigations in irritable bowel syndrome. <i>Frontline Gastroenterology</i> , 2020 , 11, 140-147	2.6	8
385	Efficacy of pharmacological therapies in patients with IBS with diarrhoea or mixed stool pattern: systematic review and network meta-analysis. <i>Gut</i> , 2020 , 69, 74-82	19.2	68
384	Predictors of Dyspareunia Among Female Patients With Inflammatory Bowel Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2020 , 18, 1000-1001	6.9	
383	Epidemiological, Clinical, and Psychological Characteristics of Individuals with Self-reported Irritable Bowel Syndrome Based on the Rome IV vs Rome III Criteria. <i>Clinical Gastroenterology and Hepatology</i> , 2020 , 18, 392-398.e2	6.9	35
382	Relative Efficacy of Tegaserod in a Systematic Review and Network Meta-analysis of Licensed Therapies for Irritable Bowel Syndrome With Constipation. <i>Clinical Gastroenterology and Hepatology</i> , 2020 , 18, 1238-1239.e1	6.9	33
381	Global burden of irritable bowel syndrome: trends, predictions and risk factors. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2020 , 17, 473-486	24.2	75
380	Treatment of irritable bowel syndrome with diarrhoea using titrated ondansetron (TRITON): study protocol for a randomised controlled trial. <i>Trials</i> , 2019 , 20, 517	2.8	6
379	Efficacy of drugs in chronic idiopathic constipation: a systematic review and network meta-analysis. <i>The Lancet Gastroenterology and Hepatology</i> , 2019 , 4, 831-844	18.8	42
378	Mizagliflozin for the Treatment of Functional Constipation: Are New Drugs Better?. <i>Gastroenterology</i> , 2019 , 156, 818-820	13.3	1

377	Functional Gastrointestinal Symptoms in Inflammatory Bowel Disease: Rising to the Challenge. <i>Clinical Gastroenterology and Hepatology</i> , 2019 , 17, 572-573	6.9	1
376	Prevalence of, and predictors of, bile acid diarrhea in outpatients with chronic diarrhea: A follow-up study. <i>Neurogastroenterology and Motility</i> , 2019 , 31, e13666	4	9
375	Systematic review with meta-analysis: efficacy of faecal microbiota transplantation for the treatment of irritable bowel syndrome. <i>Alimentary Pharmacology and Therapeutics</i> , 2019 , 50, 240-248	6.1	86
374	Depression, Antidepressants, and Inflammatory Bowel Disease: Implications for Future Models of Care. <i>Gastroenterology</i> , 2019 , 156, 2345-2347	13.3	2
373	Response to Letter by Moulton et al. <i>Inflammatory Bowel Diseases</i> , 2019 , 25, e99	4.5	
372	Letter: meta-analysis of prebiotics, probiotics, synbiotics and antibiotics in IBS. Authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2019 , 49, 1254-1255	6.1	1
371	Randomized controlled trial: a pilot study of a psychoeducational intervention for fatigue in patients with quiescent inflammatory bowel disease. <i>Therapeutic Advances in Chronic Disease</i> , 2019 , 10, 2040622319838439	4.9	7
370	Acupuncture and related therapies for treating irritable bowel syndrome: overview of systematic reviews and network meta-analysis. <i>Therapeutic Advances in Gastroenterology</i> , 2019 , 12, 1756284818820438	4.7	17
369	Assessing the efficacy of peripherally acting μ -opioid receptor antagonists (PAMORAs) in the treatment of opioid-induced constipation: authors reply. <i>Gut</i> , 2019 , 68, 1530-1531	19.2	1
368	Efficacy of pharmacological therapies for the treatment of opioid-induced constipation: systematic review and network meta-analysis. <i>Gut</i> , 2019 , 68, 434-444	19.2	39
367	The influence of the brain-gut axis in inflammatory bowel disease and possible implications for treatment. <i>The Lancet Gastroenterology and Hepatology</i> , 2019 , 4, 632-642	18.8	66
366	Incidence of Bloodstream Infections, Length of Hospital Stay, and Survival in Patients With Recurrent <i>Clostridioides difficile</i> Infection Treated With Fecal Microbiota Transplantation or Antibiotics: A Prospective Cohort Study. <i>Annals of Internal Medicine</i> , 2019 , 171, 695-702	8	50
365	Crohn's Disease Connectome Conundrums: Relevance to the Prevalence and Management of Mood Disorders. <i>Gastroenterology</i> , 2019 , 157, 1429-1430	13.3	
364	Relative Efficacy of Naloxegol and Polyethylene Glycol 3350 in Opioid-Induced Constipation. <i>American Journal of Gastroenterology</i> , 2019 , 114, 1694	0.7	1
363	Effectiveness of management strategies for uninvestigated dyspepsia: systematic review and network meta-analysis. <i>BMJ, The</i> , 2019 , 367, l6483	5.9	17
362	Effect of Antidepressants and Psychological Therapies in Irritable Bowel Syndrome: An Updated Systematic Review and Meta-Analysis. <i>American Journal of Gastroenterology</i> , 2019 , 114, 21-39	0.7	185
361	Systematic Review and Network Meta-Analysis of Medical Therapies to Prevent Recurrence of Post-Operative Crohn's Disease. <i>Journal of Crohns and Colitis</i> , 2019 , 13, 693-701	1.5	17
360	Systematic Review and Meta-analysis: Optimal Salvage Therapy in Acute Severe Ulcerative Colitis. <i>Inflammatory Bowel Diseases</i> , 2019 , 25, 1169-1186	4.5	37

359	Development of a real-time patient-reported outcome measure for symptom assessment in patients with functional dyspepsia using the experience sampling method. <i>Neurogastroenterology and Motility</i> , 2019 , 31, e13496	4	8
358	Anxiety But Not Depression Predicts Poor Outcomes in Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , 2019 , 25, 1255-1261	4.5	20
357	Efficacy of glutamine in postinfection IBS. <i>Gut</i> , 2019 , 68, 1905-1906	19.2	3
356	Defining the relationship between depression and disease activity in IBD using clinical disease activity indices: merit or misnomer?. <i>American Journal of Gastroenterology</i> , 2018 , 113, 773-774	0.7	
355	Histologic Criteria to Define Irritable Bowel Syndrome: Within the Realms of Possibility?. <i>Gastroenterology</i> , 2018 , 154, 1539-1541	13.3	0
354	Factors affecting clinical decision-making in inflammatory bowel disease and the role of point-of-care calprotectin. <i>Therapeutic Advances in Gastroenterology</i> , 2018 , 11, 1756283X17744739	4.7	10
353	Proton pump inhibitors and oesophageal cancer: Flawed methodology and false alarms. <i>Cancer Epidemiology</i> , 2018 , 54, 137-138	2.8	
352	Efficacy and tolerability of initiating, or switching to, infliximab biosimilar CT-P13 in inflammatory bowel disease (IBD): a large single-centre experience. <i>Scandinavian Journal of Gastroenterology</i> , 2018 , 53, 700-707	2.4	26
351	No Significant Association Between the Fecal Microbiome and the Presence of Irritable Bowel Syndrome-type Symptoms in Patients with Quiescent Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , 2018 , 24, 1597-1605	4.5	13
350	Longitudinal impact of IBS-type symptoms on disease activity, healthcare utilization, psychological health, and quality of life in inflammatory bowel disease. <i>American Journal of Gastroenterology</i> , 2018 , 113, 702-712	0.7	42
349	Bi-directionality of Brain-Gut Interactions in Patients With Inflammatory Bowel Disease. <i>Gastroenterology</i> , 2018 , 154, 1635-1646.e3	13.3	148
348	Possible Redundant Data in the Network Meta-analysis of Pharmacological Therapies for Opioid-Induced Constipation. <i>Journal of Pain and Symptom Management</i> , 2018 , 55, e8-e9	4.8	3
347	Defining the functional gastrointestinal disorders is challenging: are clinical symptoms alone sufficient?. <i>Scandinavian Journal of Gastroenterology</i> , 2018 , 53, 140	2.4	
346	Fatigue in Inflammatory Bowel Disease Reflects Mood and Symptom-Reporting Behavior Rather Than Biochemical Activity or Anemia. <i>Clinical Gastroenterology and Hepatology</i> , 2018 , 16, 1165-1167	6.9	10
345	Neuromodulators for Functional Gastrointestinal Disorders (Disorders of Gut-Brain Interaction): A Rome Foundation Working Team Report. <i>Gastroenterology</i> , 2018 , 154, 1140-1171.e1	13.3	155
344	Efficacy of linaclotide in irritable bowel syndrome with constipation: Real-world data. <i>Neurogastroenterology and Motility</i> , 2018 , 30, e13328	4	
343	Global prevalence of, and risk factors for, gastro-oesophageal reflux symptoms: a meta-analysis. <i>Gut</i> , 2018 , 67, 430-440	19.2	197
342	Cyclic vomiting syndrome: a case series and review of the literature. <i>Frontline Gastroenterology</i> , 2018 , 9, 2-9	2.6	11

341	Cyclic vomiting syndrome is a prevalent and under-recognized condition in the gastroenterology outpatient clinic. <i>Neurogastroenterology and Motility</i> , 2018 , 30, e13174	4	25
340	General practitioners' perceptions of irritable bowel syndrome: a Q-methodological study. <i>Family Practice</i> , 2018 , 35, 74-79	1.9	5
339	Stool as a treatment for IBS: more questions than answers?. <i>The Lancet Gastroenterology and Hepatology</i> , 2018 , 3, 2-3	18.8	5
338	A Systematic Review and Meta-Analysis Evaluating the Efficacy of a Gluten-Free Diet and a Low FODMAPs Diet in Treating Symptoms of Irritable Bowel Syndrome. <i>American Journal of Gastroenterology</i> , 2018 , 113, 1290-1300	0.7	173
337	Chronic idiopathic constipation in adults: epidemiology, pathophysiology, diagnosis and clinical management. <i>Medical Journal of Australia</i> , 2018 , 209, 86-91	4	40
336	High prevalence of irritable bowel syndrome-type symptoms in microscopic colitis: implications for treatment. <i>Therapeutic Advances in Gastroenterology</i> , 2018 , 11, 1756284818783600	4.7	7
335	Utility of the Oral Capsaicin Test in Diagnosing Functional Dyspepsia. <i>American Journal of Gastroenterology</i> , 2018 , 113, 1257-1258	0.7	1
334	Clinical application of dietary therapies in irritable bowel syndrome. <i>Journal of Gastrointestinal and Liver Diseases</i> , 2018 , 27, 307-316	1.4	20
333	Quality of Care and the Irritable Bowel Syndrome: Is Now the Time to Set Standards?. <i>American Journal of Gastroenterology</i> , 2018 , 113, 167-169	0.7	9
332	The Glasgow Prognostic Score at the Time of Palliative Esophageal Stent Insertion is a Predictive Factor of 30-Day Mortality and Overall Survival. <i>Journal of Clinical Gastroenterology</i> , 2018 , 52, 223-228	3	3
331	Prevalence of Dyspepsia in Individuals With Gastroesophageal Reflux-Type Symptoms in the Community: A Systematic Review and Meta-analysis. <i>Clinical Gastroenterology and Hepatology</i> , 2018 , 16, 39-48.e1	6.9	21
330	Probiotics for Treating Irritable Bowel Syndrome: Are Bugs the Best Drugs?. <i>Gastroenterology</i> , 2018 , 155, 2019-2021	13.3	1
329	Insights into the evaluation and management of dyspepsia: recent developments and new guidelines. <i>Therapeutic Advances in Gastroenterology</i> , 2018 , 11, 1756284818805597	4.7	13
328	Systematic review with meta-analysis: the efficacy of prebiotics, probiotics, synbiotics and antibiotics in irritable bowel syndrome. <i>Alimentary Pharmacology and Therapeutics</i> , 2018 , 48, 1044-1060	6.1	248
327	Fatigue and its associated factors in microscopic colitis. <i>Therapeutic Advances in Gastroenterology</i> , 2018 , 11, 1756284818799599	4.7	6
326	Intending to Treat Patients With Irritable Bowel Syndrome With Cognitive-Behavioral Therapy. <i>Gastroenterology</i> , 2018 , 155, 2024	13.3	0
325	Efficacy of Secretagogues in Patients With Irritable Bowel Syndrome With Constipation: Systematic Review and Network Meta-analysis. <i>Gastroenterology</i> , 2018 , 155, 1753-1763	13.3	72
324	Low-dose imipramine for refractory functional dyspepsia: a randomised, double-blind, placebo-controlled trial. <i>The Lancet Gastroenterology and Hepatology</i> , 2018 , 3, 837-844	18.8	21

323	Reply. <i>Gastroenterology</i> , 2018 , 155, 1652-1653	13.3	
322	Gastroparesis. <i>Nature Reviews Disease Primers</i> , 2018 , 4, 41	51.1	138
321	The Effect of Antidepressants on the Course of Inflammatory Bowel Disease. <i>Canadian Journal of Gastroenterology and Hepatology</i> , 2018 , 2018, 2047242	2.8	10
320	American College of Gastroenterology Monograph on Management of Irritable Bowel Syndrome. <i>American Journal of Gastroenterology</i> , 2018 , 113, 1-18	0.7	170
319	Efficacy of psychotropic drugs in functional dyspepsia: systematic review and meta-analysis. <i>Gut</i> , 2017 , 66, 411-420	19.2	96
318	Negative Effects on Psychological Health and Quality of Life of Genuine Irritable Bowel Syndrome-type Symptoms in Patients With Inflammatory Bowel Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2017 , 15, 376-384.e5	6.9	57
317	Minimal differences in prevalence and spectrum of organic disease at upper gastrointestinal endoscopy between selected secondary care patients with symptoms of gastro-oesophageal reflux or dyspepsia. <i>Scandinavian Journal of Gastroenterology</i> , 2017 , 52, 396-402	2.4	3
316	Derivation and validation of a diagnostic test for irritable bowel syndrome using latent class analysis. <i>Alimentary Pharmacology and Therapeutics</i> , 2017 , 45, 824-832	6.1	7
315	Effect of psychological therapy on disease activity, psychological comorbidity, and quality of life in inflammatory bowel disease: a systematic review and meta-analysis. <i>The Lancet Gastroenterology and Hepatology</i> , 2017 , 2, 189-199	18.8	152
314	Letter: causes of fatigue in inflammatory bowel disease remain uncertain. <i>Alimentary Pharmacology and Therapeutics</i> , 2017 , 45, 762-763	6.1	4
313	Safety of Adding Oats to a Gluten-Free Diet for Patients With Celiac Disease: Systematic Review and Meta-analysis of Clinical and Observational Studies. <i>Gastroenterology</i> , 2017 , 153, 395-409.e3	13.3	62
312	Reply. <i>Clinical Gastroenterology and Hepatology</i> , 2017 , 15, 1315-1316	6.9	
311	Reactive Versus Proactive Therapeutic Drug Monitoring in Inflammatory Bowel Disease Patients Treated With Infliximab: A Self-Fulfilling Prophecy. <i>Clinical Gastroenterology and Hepatology</i> , 2017 , 15, 1638	6.9	1
310	Irritable Bowel Syndrome-Type Symptoms Are Associated With Psychological Comorbidity, Reduced Quality of Life, and Health Care Use in Patients With Inflammatory Bowel Disease. <i>Gastroenterology</i> , 2017 , 153, 324-325	13.3	14
309	World Gastroenterology Organisation Global Guidelines: GERD Global Perspective on Gastroesophageal Reflux Disease. <i>Journal of Clinical Gastroenterology</i> , 2017 , 51, 467-478	3	78
308	Macroscopic findings, incidence and characteristics of microscopic colitis in a large cohort of patients from the United Kingdom. <i>Scandinavian Journal of Gastroenterology</i> , 2017 , 52, 988-994	2.4	20
307	Postoperative prophylaxis in Crohn's disease after intestinal resection: a retrospective analysis. <i>Frontline Gastroenterology</i> , 2017 , 8, 203-209	2.6	6
306	Letter: NICE referral criteria for lower gastrointestinal alarm features - not ideal but not poor either. Authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2017 , 45, 1176	6.1	

305	Population screening and treatment of Helicobacter pylori infection. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2017 , 14, 230-240	24.2	96
304	Infliximab Therapeutic Drug Monitoring Changes Clinical Decisions in a Virtual Biologics Clinic for Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , 2017 , 23, 2083-2088	4.5	13
303	De novo design of covalently constrained mesosize protein scaffolds with unique tertiary structures. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2017 , 114, 10852-10857	11.5	44
302	Use of Probiotics in Hospitalized Adults to Prevent Clostridium difficile Infection: DownGRADE the Quality of Evidence?. <i>Gastroenterology</i> , 2017 , 153, 1451-1452	13.3	3
301	Faecal microbiota transplantation for Clostridium difficile-associated diarrhoea: a systematic review of randomised controlled trials. <i>Medical Journal of Australia</i> , 2017 , 207, 166-172	4	83
300	Probiotic Bifidobacterium longum NCC3001 Reduces Depression Scores and Alters Brain Activity: A Pilot Study in Patients With Irritable Bowel Syndrome. <i>Gastroenterology</i> , 2017 , 153, 448-459.e8	13.3	358
299	Multiple myeloma presenting in association with gastric phytobezoar. <i>Clinical Case Reports (discontinued)</i> , 2017 , 5, 1493-1495	0.7	3
298	Ongoing Symptoms in Ulcerative Colitis Patients in Remission: Irritable Bowel Syndrome or Gastrointestinal Symptoms in the Absence of Inflammation?. <i>Inflammatory Bowel Diseases</i> , 2017 , 23, E4-E5	4.5	6
297	Chronic constipation. <i>Nature Reviews Disease Primers</i> , 2017 , 3, 17095	51.1	106
296	Making a positive diagnosis of irritable bowel syndrome. <i>British Journal of General Practice</i> , 2017 , 67, 580-581	1.6	2
295	A Bidirectional Relationship Between Symptom Reporting and Perceived Stress, But Not Disease Activity, in Inflammatory Bowel Disease: More Questions Than Answers?. <i>Gastroenterology</i> , 2017 , 153, 1444-1445	13.3	4
294	Cyclic Vomiting Syndrome: Randomized Controlled Trials Are also Needed in Adults. <i>American Journal of Gastroenterology</i> , 2017 , 112, 1752-1753	0.7	4
293	Irritable Bowel Syndrome. <i>New England Journal of Medicine</i> , 2017 , 376, 2566-2578	59.2	291
292	Systematic review with meta-analysis: the efficacy of probiotics in inflammatory bowel disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2017 , 46, 389-400	6.1	206
291	The relationship between different information sources and disease-related patient knowledge and anxiety in patients with inflammatory bowel disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2017 , 45, 63-74	6.1	25
290	Screening for Celiac Disease in Irritable Bowel Syndrome: An Updated Systematic Review and Meta-analysis. <i>American Journal of Gastroenterology</i> , 2017 , 112, 65-76	0.7	70
289	Poor predictive value of lower gastrointestinal alarm features in the diagnosis of colorectal cancer in 1981 patients in secondary care. <i>Alimentary Pharmacology and Therapeutics</i> , 2017 , 45, 91-99	6.1	9
288	Pharmacotherapy for Irritable Bowel Syndrome. <i>Journal of Clinical Medicine</i> , 2017 , 6,	5.1	17

287	Irritable Bowel Syndrome: Pathophysiology and Current Therapeutic Approaches. <i>Handbook of Experimental Pharmacology</i> , 2017 , 239, 75-113	3.2	17
286	Efficacy of mesalazine in IBS. <i>Gut</i> , 2016 , 65, 187-8	19.2	1
285	The Importance of Smoking Cessation in Improving Disease Course in Crohn's Disease. <i>American Journal of Gastroenterology</i> , 2016 , 111, 1198	0.7	8
284	Systematic review with meta-analysis: the effect of tobacco smoking on the natural history of ulcerative colitis. <i>Alimentary Pharmacology and Therapeutics</i> , 2016 , 44, 117-26	6.1	42
283	Diagnosis: Rome IV criteria for FGIDs - an improvement or more of the same?. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2016 , 13, 501-2	24.2	27
282	Derivation and Validation of a Panel of Exhaled Volatile Organic Compounds in Differentiating Irritable Bowel Syndrome From Health. <i>Gastroenterology</i> , 2016 , 151, 1245-1246	13.3	
281	Response to Levenstein and Prantera. <i>American Journal of Gastroenterology</i> , 2016 , 111, 1499	0.7	
280	PTU-128 Prevalence and Management of Irritable Bowel Syndrome Seen in Colorectal Surgery and Gastroenterology Clinics. <i>Gut</i> , 2016 , 65, A120.1-A120	19.2	
279	PTU-137 Enhanced Diagnostic Performance of Symptom-Based Criteria for Irritable Bowel Syndrome by History and Diagnostic Evaluation. <i>Gut</i> , 2016 , 65, A125.1-A125	19.2	
278	Letter: deleterious effects of smoking on post-operative Crohn's disease - authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2016 , 43, 1248	6.1	
277	PTU-117 Screening for Coeliac Disease in Irritable Bowel Syndrome Is Still Worthwhile: An Updated Systematic Review and Meta-Analysis. <i>Gut</i> , 2016 , 65, A113.2-A113	19.2	
276	Validation and modification of a diagnostic scoring system to predict microscopic colitis. <i>Scandinavian Journal of Gastroenterology</i> , 2016 , 51, 1206-12	2.4	13
275	Antibiotic use and subsequent development of functional gastrointestinal disorders: effect of symptom-reporting and consultation behavior. <i>Neurogastroenterology and Motility</i> , 2016 , 28, 449-50	4	
274	Ipilimumab-induced colitis: experience from a tertiary referral center. <i>Therapeutic Advances in Gastroenterology</i> , 2016 , 9, 457-62	4.7	23
273	Simple Clinical Colitis Activity Index: Accurate Assessment of Inflammatory Burden or Reflection of Low Mood and Somatoform Behavior?. <i>American Journal of Gastroenterology</i> , 2016 , 111, 900-1	0.7	1
272	Rifaximin for the treatment of diarrhea-predominant irritable bowel syndrome. <i>Expert Review of Gastroenterology and Hepatology</i> , 2016 , 10, 431-42	4.2	19
271	Irritable Bowel Syndrome and Microscopic Colitis: A Systematic Review and Meta-analysis. <i>Clinical Gastroenterology and Hepatology</i> , 2016 , 14, 659-68.e1; quiz e54-5	6.9	45
270	Psychological Comorbidity and Inflammatory Bowel Disease Activity: Cause or Effect?. <i>Clinical Gastroenterology and Hepatology</i> , 2016 , 14, 1061-2	6.9	1

269	Poor Correlation Between Patient-reported and Endoscopic Components of the Mayo Score in Ulcerative Colitis. <i>Gastroenterology</i> , 2016 , 150, 1037-9	13.3	3
268	Functional Dyspepsia. <i>New England Journal of Medicine</i> , 2016 , 374, 896	59.2	17
267	The possible risks of proton pump inhibitors. <i>Medical Journal of Australia</i> , 2016 , 205, 292-3	4	6
266	Evaluation of a faecal calprotectin care pathway for use in primary care. <i>Primary Health Care Research and Development</i> , 2016 , 17, 428-36	1.6	19
265	Systematic review with meta-analysis: the adverse effects of tobacco smoking on the natural history of Crohn's disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2016 , 43, 549-61	6.1	102
264	Clinical and epidemiological differences in functional dyspepsia between the East and the West. <i>Neurogastroenterology and Motility</i> , 2016 , 28, 167-74	4	72
263	Screening for Celiac Disease in Individuals With Symptoms Suggestive of Irritable Bowel Syndrome: Still a Worthwhile Exercise. <i>Gastroenterology</i> , 2016 , 151, 368-70	13.3	1
262	Eradication therapy for peptic ulcer disease in Helicobacter pylori-positive people. <i>The Cochrane Library</i> , 2016 , 4, CD003840	5.2	33
261	PTU-127 Efficacy of Linaclotide in Constipation-Predominant Irritable Bowel Syndrome in Routine Clinical Practice: A Multicentre Experience. <i>Gut</i> , 2016 , 65, A119-A119	19.2	1
260	Poor Correlation Between Clinical Disease Activity and Mucosal Inflammation, and the Role of Psychological Comorbidity, in Inflammatory Bowel Disease. <i>American Journal of Gastroenterology</i> , 2016 , 111, 541-51	0.7	84
259	Reply. <i>Clinical Gastroenterology and Hepatology</i> , 2016 , 14, 779	6.9	
258	Imipramine for Treatment of Esophageal Hypersensitivity and Functional Heartburn. <i>American Journal of Gastroenterology</i> , 2016 , 111, 1358	0.7	3
257	Depression Is Associated With Subjective Measures of Crohn's Disease Activity During Longitudinal Follow-up. <i>Gastroenterology</i> , 2016 , 151, 762-3	13.3	1
256	Pathophysiology of irritable bowel syndrome. <i>The Lancet Gastroenterology and Hepatology</i> , 2016 , 1, 133-146	13.3	224
255	Enhancing Diagnostic Performance of Symptom-Based Criteria for Irritable Bowel Syndrome by Additional History and Limited Diagnostic Evaluation. <i>American Journal of Gastroenterology</i> , 2016 , 111, 1446-1454	0.7	26
254	Letter: smoking as a modifiable risk factor for a complicated course in Crohn's disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2016 , 43, 440	6.1	
253	Letter: biologics are effective in neutralising the detrimental effect of smoking on the natural course of Crohn's disease - authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2016 , 43, 1246	6.1	
252	Development and validation of a scoring system to identify patients with microscopic colitis. <i>Clinical Gastroenterology and Hepatology</i> , 2015 , 13, 1125-31	6.9	31

251	Lubiprostone Is Effective in Treating Functional Bowel Disease With Constipation. <i>Clinical Gastroenterology and Hepatology</i> , 2015 , 13, 1378-9	6.9	1
250	Pinaverium in Irritable Bowel Syndrome: Old Drug, New Tricks?. <i>Clinical Gastroenterology and Hepatology</i> , 2015 , 13, 1548-9	6.9	
249	Comment on "A randomized clinical trial of <i>Saccharomyces cerevisiae</i> versus placebo in the irritable bowel syndrome" by Guillaume Pineton de Chambrun et al. [Digestive and Liver Disease 2015;47:119-24]. <i>Digestive and Liver Disease</i> , 2015 , 47, 437	3.3	
248	Irritable Bowel Syndrome and Colorectal Neoplasia: "Cause and Effect" or Chance Association?. <i>Gastroenterology</i> , 2015 , 149, 502-3	13.3	
247	Long-term efficacy and safety of azathioprine in ulcerative colitis. <i>Journal of Crohns and Colitis</i> , 2015 , 9, 191-7	1.5	18
246	Ondansetron and irritable bowel syndrome. <i>Gut</i> , 2015 , 64, 1181	19.2	1
245	VSL#3 in Postoperative Crohn's Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2015 , 13, 1855	6.9	1
244	High Prevalence of Idiopathic Bile Acid Diarrhea Among Patients With Diarrhea-Predominant Irritable Bowel Syndrome Based on Rome III Criteria. <i>Clinical Gastroenterology and Hepatology</i> , 2015 , 13, 1650-5.e2	6.9	60
243	Beliefs about management of irritable bowel syndrome in primary care: cross-sectional survey in one locality. <i>Primary Health Care Research and Development</i> , 2015 , 16, 263-9	1.6	19
242	Lack of utility of symptoms and signs at first presentation as predictors of inflammatory bowel disease in secondary care. <i>American Journal of Gastroenterology</i> , 2015 , 110, 716-24	0.7	14
241	Irritable bowel syndrome is significantly associated with somatisation in 840 patients, which may drive bloating. <i>Alimentary Pharmacology and Therapeutics</i> , 2015 , 41, 449-58	6.1	41
240	Defining the relationship between clinical and biochemical disease activity indices and perceived stress in inflammatory bowel disease. <i>Gastroenterology</i> , 2015 , 149, 1632-4	13.3	0
239	Functional Dyspepsia. <i>New England Journal of Medicine</i> , 2015 , 373, 1853-63	59.2	268
238	Efficacy of hypnotherapy in one thousand patients with irritable bowel syndrome. <i>Alimentary Pharmacology and Therapeutics</i> , 2015 , 41, 1222-3	6.1	
237	The Effect of Dietary Intervention on Irritable Bowel Syndrome: A Systematic Review. <i>Clinical and Translational Gastroenterology</i> , 2015 , 6, e107	4.2	37
236	Central pain processing in irritable bowel syndrome is modulated by mood: a mechanism for the beneficial effects of antidepressants?. <i>Gastroenterology</i> , 2015 , 148, 247-8	13.3	1
235	Screening for bile acid diarrhoea in suspected irritable bowel syndrome. <i>Gut</i> , 2015 , 64, 851	19.2	6
234	Global prevalence of, and risk factors for, uninvestigated dyspepsia: a meta-analysis. <i>Gut</i> , 2015 , 64, 1049-57	15.2	253

233	Functional dyspepsia. <i>Current Opinion in Gastroenterology</i> , 2015 , 31, 492-8	3	17
232	Letter: irritable bowel syndrome is significantly associated with somatisation - authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2015 , 41, 791-2	6.1	
231	Letter: therapeutic trial is more informative than SeHCAT to diagnose bile acid malabsorption--authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2015 , 42, 781	6.1	
230	PTU-068 Outcomes of disease modifying therapy delivered to crohn's disease patients following intestinal resection. <i>Gut</i> , 2015 , 64, A90.1-A90	19.2	
229	Use of Biomarkers in Irritable Bowel Syndrome: To Predict the Future, Look at the Past. <i>Clinical and Translational Gastroenterology</i> , 2015 , 6, e116	4.2	6
228	Symbiotics in irritable bowel syndrome--better than probiotics alone?. <i>Current Opinion in Clinical Nutrition and Metabolic Care</i> , 2015 , 18, 485-9	3.8	4
227	No increase in prevalence of somatization in functional vs organic dyspepsia: a cross-sectional survey. <i>Neurogastroenterology and Motility</i> , 2015 , 27, 1024-31	4	15
226	PTU-067 How are postoperative crohn's patients followed up? a retrospective analysis from a tertiary referral centre. <i>Gut</i> , 2015 , 64, A89.2-A89	19.2	
225	Systematic review and meta-analysis: opportunistic infections and malignancies during treatment with anti-integrin antibodies in inflammatory bowel disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2015 , 41, 1227-36	6.1	51
224	Systematic review with meta-analysis: the prevalence of bile acid malabsorption in the irritable bowel syndrome with diarrhoea. <i>Alimentary Pharmacology and Therapeutics</i> , 2015 , 42, 3-11	6.1	111
223	Systematic review with meta-analysis: the accuracy of diagnosing irritable bowel syndrome with symptoms, biomarkers and/or psychological markers. <i>Alimentary Pharmacology and Therapeutics</i> , 2015 , 42, 491-503	6.1	54
222	Irritable bowel syndrome and somatization. <i>Neurogastroenterology and Motility</i> , 2015 , 27, 740	4	2
221	Helicobacter pylori eradication for the prevention of gastric neoplasia. <i>Cochrane Database of Systematic Reviews</i> , 2015 , CD005583		43
220	PTU-066 Characteristics and outcomes of patients undergoing second intestinal resection for crohn's disease in a tertiary referral centre. <i>Gut</i> , 2015 , 64, A89.1-A89	19.2	
219	PTU-089 Are clinical indices of inflammatory bowel disease activity superior to patient opinion at predicting activity as defined by faecal calprotectin?. <i>Gut</i> , 2015 , 64, A100.1-A100	19.2	
218	PTU-090 Prevalence and impact of irritable bowel type-symptoms in quiescent inflammatory bowel disease. <i>Gut</i> , 2015 , 64, A100.2-A100	19.2	
217	PTU-065 The influence of smoking on need for surgery and post-operative outcomes in crohn's disease. <i>Gut</i> , 2015 , 64, A88.2-A89	19.2	
216	IBS-like symptoms in patients with ulcerative colitis. <i>Clinical and Experimental Gastroenterology</i> , 2015 , 8, 101-9	3.1	24

215	PTU-176 Systematic review with meta-analysis: prevalence of bile acid malabsorption in irritable bowel syndrome with diarrhoea. <i>Gut</i> , 2015 , 64, A140.2-A141	19.2	
214	PTU-086 Outcomes of all surgery for ulcerative colitis over a 12-month period at a tertiary referral ibd unit. <i>Gut</i> , 2015 , 64, A98.2-A99	19.2	
213	Anxiety and Depression Increase in a Stepwise Manner in Parallel With Multiple FGIDs and Symptom Severity and Frequency. <i>American Journal of Gastroenterology</i> , 2015 , 110, 1038-48	0.7	81
212	Reducing the need for random colonic biopsies in patients with diarrhea. <i>American Journal of Gastroenterology</i> , 2015 , 110, 351-2	0.7	5
211	Combining biomarkers in irritable bowel syndrome: a forward step toward making a positive diagnosis and directing therapy?. <i>Gastroenterology</i> , 2015 , 148, 1471-3	13.3	1
210	Do Lay People Accept a Positive Diagnosis of Irritable Bowel Syndrome?. <i>Gastroenterology</i> , 2015 , 149, 252-3	13.3	3
209	Efficacy of tumour necrosis factor antagonists on remission, colectomy and hospitalisations in ulcerative colitis: Meta-analysis of placebo-controlled trials. <i>Digestive and Liver Disease</i> , 2015 , 47, 356-64	3.3	29
208	Prevalence of organic disease at colonoscopy in patients with symptoms compatible with irritable bowel syndrome: cross-sectional survey. <i>Scandinavian Journal of Gastroenterology</i> , 2015 , 50, 816-23	2.4	46
207	Aetiopathogenesis of functional dyspepsia. <i>Gut</i> , 2015 , 64, 1182-3	19.2	2
206	Irritable bowel syndrome: dietary interventions. <i>Clinical Evidence</i> , 2015 , 2015,		2
205	Helicobacter pylori eradication: gastric cancer prevention. <i>Clinical Evidence</i> , 2015 , 2015,		1
204	Characteristics of functional bowel disorder patients: a cross-sectional survey using the Rome III criteria. <i>Alimentary Pharmacology and Therapeutics</i> , 2014 , 39, 312-21	6.1	76
203	The Rome III criteria for the diagnosis of functional dyspepsia in secondary care are not superior to previous definitions. <i>Gastroenterology</i> , 2014 , 146, 932-40; quiz e14-5	13.3	60
202	Increased prevalence of autoimmune diseases in functional gastrointestinal disorders: case-control study of 23471 primary care patients. <i>Alimentary Pharmacology and Therapeutics</i> , 2014 , 40, 827-34	6.1	24
201	Letter: is there a bi-directional relationship between depression and IBD?. <i>Alimentary Pharmacology and Therapeutics</i> , 2014 , 40, 213	6.1	0
200	Systematic review: The epidemiology of the hepatobiliary manifestations in patients with inflammatory bowel disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2014 , 40, 3-15	6.1	76
199	Functional bowel symptoms in quiescent inflammatory bowel disease: more than just irritable bowel syndrome?. <i>Gastroenterology</i> , 2014 , 147, 1176-7	13.3	5
198	Efficacy of prebiotics, probiotics, and synbiotics in irritable bowel syndrome and chronic idiopathic constipation: systematic review and meta-analysis. <i>American Journal of Gastroenterology</i> , 2014 , 109, 1547-61; quiz 1546, 1562	0.7	447

197	Polyethylene glycol in constipation-predominant irritable bowel syndrome. <i>American Journal of Gastroenterology</i> , 2014 , 109, 135	0.7	1
196	The fall and rise of 5-hydroxytryptamine receptor antagonists in irritable bowel syndrome with diarrhea. <i>Gastroenterology</i> , 2014 , 147, 527-8	13.3	1
195	The effect of fiber supplementation on irritable bowel syndrome: a systematic review and meta-analysis. <i>American Journal of Gastroenterology</i> , 2014 , 109, 1367-74	0.7	202
194	Diagnosis of IBS: symptoms, symptom-based criteria, biomarkers or 'psychomarkers'?. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2014 , 11, 683-91	24.2	34
193	American College of Gastroenterology monograph on the management of irritable bowel syndrome and chronic idiopathic constipation. <i>American Journal of Gastroenterology</i> , 2014 , 109 Suppl 1, S2-26; quiz S27	0.7	393
192	Whom should we "test and treat" for <i>Helicobacter pylori</i> ?. <i>BMJ, The</i> , 2014 , 348, g3320	5.9	8
191	Systematic review with meta-analysis: malignancies with anti-tumour necrosis factor- α therapy in inflammatory bowel disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2014 , 39, 447-58	6.1	112
190	Effect of antidepressants and psychological therapies, including hypnotherapy, in irritable bowel syndrome: systematic review and meta-analysis. <i>American Journal of Gastroenterology</i> , 2014 , 109, 1350-65; quiz 1366	0.7	262
189	<i>Helicobacter pylori</i> eradication therapy to prevent gastric cancer in healthy asymptomatic infected individuals: systematic review and meta-analysis of randomised controlled trials. <i>BMJ, The</i> , 2014 , 348, g3174	5.9	380
188	Masquerading gastrointestinal polyps: air on the side of caution? Cystic pneumatosis. <i>Gastroenterology</i> , 2014 , 146, e9-10	13.3	5
187	Diagnosing irritable bowel syndrome with a combination of biomarkers and "psychomarkers". <i>Gastroenterology</i> , 2014 , 146, 1418-20	13.3	1
186	Costs of adalimumab versus infliximab as first-line biological therapy for luminal Crohn's disease. <i>Journal of Crohns and Colitis</i> , 2014 , 8, 375-83	1.5	11
185	PWE-098 Earlier Use Of Azathioprine In Ulcerative Colitis Does Not Alter Subsequent Need For Hospitalisation, Biologic Therapy, Or Colectomy. <i>Gut</i> , 2014 , 63, A167.1-A167	19.2	
184	PTU-075 Systematic Review And Meta-analysis: Sensitivity And Specificity Of Tc-99m Hmpao Labelled White Cell Scintigraphy In The Diagnosis Of Active Inflammatory Bowel Disease. <i>Gut</i> , 2014 , 63, A71.2-A71	19.2	2
183	PWE-185 Beliefs About Management Of Irritable Bowel Syndrome In Primary Care: Cross-sectional Survey. <i>Gut</i> , 2014 , 63, A207.1-A207	19.2	
182	PTH-106 Bile Acid Diarrhoea Masquerades As Diarrhoea-predominant Irritable Bowel Syndrome: Results From A Dual Centre Prospective Study. <i>Gut</i> , 2014 , 63, A257.2-A258	19.2	
181	Epidemiology of Dyspepsia 2014 , 158-171		
180	How to Read a Systematic Review and Meta-Analysis 2014 , 48-57		

179	The overlap of atopy and functional gastrointestinal disorders among 23,471 patients in primary care. <i>Alimentary Pharmacology and Therapeutics</i> , 2014 , 40, 382-91	6.1	68
178	Letter: bile acid diarrhoea is not a rare cause of diarrhoea in secondary care. <i>Alimentary Pharmacology and Therapeutics</i> , 2014 , 40, 216	6.1	2
177	Placebo response rate in clinical trials of fistulizing Crohn's disease: systematic review and meta-analysis. <i>Clinical Gastroenterology and Hepatology</i> , 2014 , 12, 1981-90	6.9	21
176	Letter: effects of iron therapy after non-variceal acute upper gastrointestinal bleeding. <i>Alimentary Pharmacology and Therapeutics</i> , 2014 , 39, 346	6.1	
175	PWE-177 A Systematic Review Of Antidepressants In Irritable Bowel Syndrome: A Qualitative Analysis. <i>Gut</i> , 2014 , 63, A203.1-A203	19.2	
174	Rates of upper gastrointestinal endoscopy and gastro-oesophageal malignancy outcomes. <i>Gut</i> , 2014 , 63, 703	19.2	1
173	Prevalence of functional gastrointestinal disorders among consecutive new patient referrals to a gastroenterology clinic. <i>Frontline Gastroenterology</i> , 2014 , 5, 266-271	2.6	29
172	Death knell for placebo-controlled trials in chronic idiopathic constipation?. <i>Gastroenterology</i> , 2013 , 145, 897-8	13.3	2
171	Bathyal demersal fishes of Charlie-Gibbs Fracture Zone region (49°54'N) of the Mid-Atlantic Ridge: II. Baited camera lander observations. <i>Deep-Sea Research Part II: Topical Studies in Oceanography</i> , 2013 , 98, 397-406	2.3	14
170	Validation of the Rome III criteria for the diagnosis of irritable bowel syndrome in secondary care. <i>Gastroenterology</i> , 2013 , 145, 1262-70.e1	13.3	124
169	Efficacy of pharmacological therapies for the treatment of opioid-induced constipation: systematic review and meta-analysis. <i>American Journal of Gastroenterology</i> , 2013 , 108, 1566-74; quiz 1575	0.7	79
168	Prevalence of irritable bowel syndrome-type symptoms in patients with celiac disease: a meta-analysis. <i>Clinical Gastroenterology and Hepatology</i> , 2013 , 11, 359-65.e1	6.9	108
167	A patient with chronic diarrhea of unknown cause. <i>Clinical Gastroenterology and Hepatology</i> , 2013 , 11, e27-8	6.9	
166	First-line eradication therapy for <i>Helicobacter pylori</i> : time for a change?. <i>Gastroenterology</i> , 2013 , 144, 652-3	13.3	2
165	Preoperative use of anti-TNF therapy and postoperative complications in inflammatory bowel diseases: a meta-analysis. <i>Journal of Crohns and Colitis</i> , 2013 , 7, 853-67	1.5	142
164	Reply to Machicado JD, Villafuerte-Galvez J, Marcos LA, Prevalence of irritable bowel syndrome in South America. <i>Clinical Gastroenterology and Hepatology</i> , 2013 , 11, 102-3	6.9	2
163	NICE clinical guideline (CG152): the management of Crohn's disease in adults, children and young people. <i>Alimentary Pharmacology and Therapeutics</i> , 2013 , 37, 195-203	6.1	37
162	The natural history of gastro-oesophageal reflux symptoms in the community and its effects on survival: a longitudinal 10-year follow-up study. <i>Alimentary Pharmacology and Therapeutics</i> , 2013 , 37, 323-31	6.1	19

161	Balancing risks and benefits of prucalopride for the treatment of chronic constipation in Asians. <i>Neurogastroenterology and Motility</i> , 2013 , 25, 89	4	2
160	Association between constipation and colorectal cancer: systematic review and meta-analysis of observational studies. <i>American Journal of Gastroenterology</i> , 2013 , 108, 894-903; quiz 904	0.7	40
159	Opportunistic infections with anti-tumor necrosis factor- α therapy in inflammatory bowel disease: meta-analysis of randomized controlled trials. <i>American Journal of Gastroenterology</i> , 2013 , 108, 1268-76	0.7	247
158	Ulcerative colitis. <i>BMJ, The</i> , 2013 , 346, f432	5.9	99
157	Dyspepsia. <i>BMJ, The</i> , 2013 , 347, f5059	5.9	11
156	Linacotide: new mechanisms and new promise for treatment in constipation and irritable bowel syndrome. <i>Therapeutic Advances in Chronic Disease</i> , 2013 , 4, 268-76	4.9	7
155	Dyspepsia. <i>Current Opinion in Gastroenterology</i> , 2013 , 29, 662-8	3	16
154	Efficacy of granulocyte/monocyte apheresis for moderate to severe Crohn's disease. <i>Gut</i> , 2013 , 62, 653	19.2	2
153	Response to Neis et al. <i>American Journal of Gastroenterology</i> , 2013 , 108, 1930	0.7	
152	Initial management of dyspepsia in primary care: an evidence-based approach. <i>British Journal of General Practice</i> , 2013 , 63, 498-9	1.6	10
151	PTH-084 Endoscopic and Histological Activity as Predictors of Relapse in Patients Undergoing Surveillance Colonoscopy for Ulcerative Colitis. <i>Gut</i> , 2013 , 62, A245.2-A245	19.2	
150	PTU-136 Prevalence of Functional Gastrointestinal Disorders in Consecutive New Patient Referrals to a Gastroenterology Clinic. <i>Gut</i> , 2013 , 62, A102.2-A103	19.2	
149	PTH-194 A Retrospective Analysis of Glucose-Hydrogen Breath test for Small Intestine Bacterial Overgrowth in a Teaching Hospital. <i>Gut</i> , 2013 , 62, A290.2-A291	19.2	
148	Optimum duration of regimens for <i>Helicobacter pylori</i> eradication. <i>The Cochrane Library</i> , 2013 , CD008333	7.2	80
147	PWE-153 Association Between Constipation and Colorectal Cancer: Systematic Review and Meta-Analysis of Observational Studies. <i>Gut</i> , 2013 , 62, A193.2-A193	19.2	
146	PTH-199 Prevalence of Organic Disorders in Consecutive New Patients Meeting Criteria for IBS in a Gastroenterology Clinic. <i>Gut</i> , 2013 , 62, A292.3-A293	19.2	
145	Efficacy of infliximab in acute severe ulcerative colitis: a single-centre experience. <i>World Journal of Gastroenterology</i> , 2013 , 19, 1091-7	5.6	20
144	Letter: the effects of overlapping symptoms on the response to PPI therapy in GERD. <i>Alimentary Pharmacology and Therapeutics</i> , 2012 , 36, 207; author 207-8	6.1	1

143	Prevalence of, and predictors of, bile acid malabsorption in outpatients with chronic diarrhea. <i>Neurogastroenterology and Motility</i> , 2012 , 24, 983-e538	4	67
142	Treatment of <i>Helicobacter pylori</i> in Latin America. <i>Lancet, The</i> , 2012 , 379, 407; author reply 408-9	40	
141	Efficacy of oral vs. topical, or combined oral and topical 5-aminosalicylates, in Ulcerative Colitis: systematic review and meta-analysis. <i>American Journal of Gastroenterology</i> , 2012 , 107, 167-76; author reply 177	0.7	106
140	Efficacy of topical 5-aminosalicylates in preventing relapse of quiescent ulcerative colitis: a meta-analysis. <i>Clinical Gastroenterology and Hepatology</i> , 2012 , 10, 513-9	6.9	42
139	Irritable bowel syndrome. <i>BMJ, The</i> , 2012 , 345, e5836	5.9	59
138	Prevalence of symptoms meeting criteria for irritable bowel syndrome in inflammatory bowel disease: systematic review and meta-analysis. <i>American Journal of Gastroenterology</i> , 2012 , 107, 1474-82	0.7	357
137	Eradicating <i>Helicobacter pylori</i> in functional dyspepsia. <i>Gastroenterology</i> , 2012 , 142, 1613-4	13.3	9
136	Acupuncture for irritable bowel syndrome. <i>Gastroenterology</i> , 2012 , 143, 1683-4	13.3	4
135	Efficacy, tolerability, and predictors of response to infliximab therapy for Crohn's disease: a large single centre experience. <i>Journal of Crohns and Colitis</i> , 2012 , 6, 143-53	1.5	75
134	Prevalence of gastro-esophageal reflux-type symptoms in individuals with irritable bowel syndrome in the community: a meta-analysis. <i>American Journal of Gastroenterology</i> , 2012 , 107, 1793-801; quiz 1802	0.7	58
133	Global prevalence of and risk factors for irritable bowel syndrome: a meta-analysis. <i>Clinical Gastroenterology and Hepatology</i> , 2012 , 10, 712-721.e4	6.9	1230
132	Incidental focal colonic lesions found on (18)Fluorodeoxyglucose positron emission tomography/computed tomography scan: further support for a national guideline on definitive management. <i>Colorectal Disease</i> , 2012 , 14, e56-63	2.1	14
131	Hypertransaminasaemia and coeliac disease: authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2012 , 35, 203-204	6.1	
130	Efficacy and tolerability of methotrexate therapy for refractory Crohn's disease: a large single-centre experience. <i>Alimentary Pharmacology and Therapeutics</i> , 2012 , 35, 284-91	6.1	16
129	In irritable bowel syndrome, antispasmodics and antidepressants improve abdominal pain and global assessment and symptom scores, but there is no evidence for the effectiveness of bulking agents. <i>Evidence-Based Medicine</i> , 2012 , 17, 114-5		3
128	Laxatives for chronic constipation in adults. <i>BMJ, The</i> , 2012 , 345, e6168	5.9	11
127	Direction of the brain-gut pathway in functional gastrointestinal disorders. <i>Gut</i> , 2012 , 61, 1368	19.2	4
126	Effect of dyspepsia on survival: a longitudinal 10-year follow-up study. <i>American Journal of Gastroenterology</i> , 2012 , 107, 912-21	0.7	51

125	Effect of gender on prevalence of irritable bowel syndrome in the community: systematic review and meta-analysis. <i>American Journal of Gastroenterology</i> , 2012 , 107, 991-1000	0.7	232
124	Response to Doherty and Moss. <i>American Journal of Gastroenterology</i> , 2012 , 107, 487-488	0.7	
123	Response to Kayhan et al.. <i>American Journal of Gastroenterology</i> , 2012 , 107, 321-322	0.7	
122	OC-151 Prevalence of, and predictors of, a positive SEHCAT scan for bile acid diarrhoea in outpatients with chronic diarrhoea. <i>Gut</i> , 2012 , 61, A65.2-A65	19.2	
121	PWE-059 Prevalence of gastro-esophageal reflux disease in individuals with irritable bowel syndrome: a systematic review and meta-analysis. <i>Gut</i> , 2012 , 61, A321.1-A321	19.2	
120	PWE-060 Effect of gender on prevalence and subtype of irritable bowel syndrome: a systematic review and meta-analysis. <i>Gut</i> , 2012 , 61, A321.2-A321	19.2	
119	Irritable bowel syndrome. <i>Clinical Evidence</i> , 2012 , 2012,		7
118	Evidence-based management of ulcerative colitis. <i>Minerva Gastroenterologica E Dietologica</i> , 2012 , 58, 87-99	1.6	5
117	Symptom-based diagnostic criteria for irritable bowel syndrome: the more things change, the more they stay the same. <i>Gastroenterology Clinics of North America</i> , 2011 , 40, 87-103	4.4	15
116	Medical or surgical therapy for gastroesophageal reflux disease?. <i>Gastroenterology</i> , 2011 , 141, 1938-9	13.3	1
115	Adalimumab as second line anti-tumour necrosis factor alpha therapy for Crohn's disease: A single centre experience. <i>Journal of Crohns and Colitis</i> , 2011 , 5, 324-31	1.5	19
114	Prevalence of, and risk factors for, chronic idiopathic constipation in the community: systematic review and meta-analysis. <i>American Journal of Gastroenterology</i> , 2011 , 106, 1582-91; quiz 1581, 1592	0.7	464
113	Efficacy of biological therapies in inflammatory bowel disease: systematic review and meta-analysis. <i>American Journal of Gastroenterology</i> , 2011 , 106, 644-59, quiz 660	0.7	437
112	Efficacy of traditional chinese medicine in functional constipation. <i>American Journal of Gastroenterology</i> , 2011 , 106, 1003; author reply 1003-4	0.7	4
111	Efficacy of 5-aminosalicylates in Crohn's disease: systematic review and meta-analysis. <i>American Journal of Gastroenterology</i> , 2011 , 106, 617-29	0.7	147
110	Glucocorticosteroid therapy in inflammatory bowel disease: systematic review and meta-analysis. <i>American Journal of Gastroenterology</i> , 2011 , 106, 590-9; quiz 600	0.7	212
109	ROME III Criteria for Functional Gastrointestinal Disorders: Too Much Overlap to Be Useful?. <i>Gastroenterology</i> , 2011 , 140, S-725-S-726	13.3	3
108	Chemoprevention for gastric cancer. <i>Baillieres Best Practice and Research in Clinical Gastroenterology</i> , 2011 , 25, 581-92	2.5	18

107	VSL#3 and remission in active ulcerative colitis: larger studies required. <i>American Journal of Gastroenterology</i> , 2011 , 106, 547; author reply 547-8	0.7	4
106	<i>Helicobacter pylori</i> eradication. <i>Lancet, The</i> , 2011 , 378, 313; author reply 314	40	
105	Coeliac disease and hypertransaminasaemia: a systematic review and meta-analysis. <i>Gut</i> , 2011 , 60, A18-A182	19.2	2
104	Predictors of response and loss of response to infliximab therapy for crohn's disease: a large UK single centre experience. <i>Gut</i> , 2011 , 60, A218-A218	19.2	2
103	Adverse events associated with infliximab therapy in a large single centre UK cohort. <i>Gut</i> , 2011 , 60, A217-A218	6.1	1
102	Efficacy of antidepressants in irritable bowel syndrome: an updated systematic review and meta-analysis controlling for depression. <i>Gut</i> , 2011 , 60, A154-A155	19.2	2
101	Defining a responder in treatment trials for chronic idiopathic constipation. <i>Alimentary Pharmacology and Therapeutics</i> , 2011 , 33, 285-6; author reply 286-7	6.1	2
100	Granulocyte and monocyte adsorptive apheresis in the management of ulcerative colitis: authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2011 , 33, 289-289	6.1	
99	Potential role of granulocyte/monocyte adsorptive apheresis for ulcerative colitis with concomitant CMV infection: authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2011 , 33, 498-498	6.1	1
98	Systematic review: the effects of fibre in the management of chronic idiopathic constipation. <i>Alimentary Pharmacology and Therapeutics</i> , 2011 , 33, 895-901	6.1	161
97	Do dried plums really help constipation?. <i>Alimentary Pharmacology and Therapeutics</i> , 2011 , 33, 1258-9; author reply 1259	6.1	1
96	Meta-analysis: Coeliac disease and hypertransaminasaemia. <i>Alimentary Pharmacology and Therapeutics</i> , 2011 , 34, 33-40	6.1	58
95	Meta-analysis: the epidemiology of noncardiac chest pain in the community. <i>Alimentary Pharmacology and Therapeutics</i> , 2011 , 34, 172-80	6.1	35
94	Is otilonium bromide globally effective in irritable bowel syndrome?. <i>Alimentary Pharmacology and Therapeutics</i> , 2011 , 34, 1034-5; author reply 1035-6	6.1	2
93	Mucosal inflammation as a potential etiological factor in irritable bowel syndrome: a systematic review. <i>Journal of Gastroenterology</i> , 2011 , 46, 421-31	6.9	134
92	Effect of laxatives and pharmacological therapies in chronic idiopathic constipation: systematic review and meta-analysis. <i>Gut</i> , 2011 , 60, 209-18	19.2	240
91	IBS in 2010: advances in pathophysiology, diagnosis and treatment. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2011 , 8, 76-8	24.2	18
90	Antibiotic therapy in inflammatory bowel disease: a systematic review and meta-analysis. <i>American Journal of Gastroenterology</i> , 2011 , 106, 661-73	0.7	390

89	5-aminosalicylates prevent relapse of Crohn's disease after surgically induced remission: systematic review and meta-analysis. <i>American Journal of Gastroenterology</i> , 2011 , 106, 413-20	0.7	82
88	Treatment of irritable bowel syndrome: beyond fiber and antispasmodic agents. <i>Therapeutic Advances in Gastroenterology</i> , 2011 , 4, 115-27	4.7	24
87	Efficacy of 5-aminosalicylates in ulcerative colitis: systematic review and meta-analysis. <i>American Journal of Gastroenterology</i> , 2011 , 106, 601-16	0.7	176
86	Losses to follow-up limit conclusions regarding the efficacy of branched-chain amino acids in patients with hepatic encephalopathy. <i>American Journal of Gastroenterology</i> , 2011 , 106, 1718; author reply 1718-9	0.7	
85	Response to Atreja et al.. <i>American Journal of Gastroenterology</i> , 2011 , 106, 2046	0.7	
84	Response to Yang et al.. <i>American Journal of Gastroenterology</i> , 2011 , 106, 2044	0.7	
83	Efficacy of immunosuppressive therapy for inflammatory bowel disease: a systematic review and meta-analysis. <i>American Journal of Gastroenterology</i> , 2011 , 106, 630-42	0.7	183
82	Once-daily dosing vs. conventional dosing schedule of mesalamine and relapse of quiescent ulcerative colitis: systematic review and meta-analysis. <i>American Journal of Gastroenterology</i> , 2011 , 106, 2070-7; quiz 2078	0.7	47
81	Reply to Akobeng. <i>American Journal of Gastroenterology</i> , 2011 , 106, 1857-1858	0.7	
80	Rome III criteria for functional gastrointestinal disorders: too much overlap to be useful?. <i>Gut</i> , 2011 , 60, A25-A25	19.2	
79	Utility of fecal calprotectin in differentiating active inflammatory bowel disease from coexistent irritable bowel syndrome. <i>American Journal of Gastroenterology</i> , 2011 , 106, 166; author reply 166-7	0.7	4
78	Applicability of the reported prevalence of bile salt malabsorption in irritable bowel. <i>Alimentary Pharmacology and Therapeutics</i> , 2010 , 31, 161-2; author reply 162-4	6.1	3
77	Alverine citrate, simeticone, and Rome III irritable bowel syndrome. <i>Alimentary Pharmacology and Therapeutics</i> , 2010 , 31, 767-8; author reply 768-9	6.1	3
76	Probiotics in irritable bowel syndrome: underachievers or underpowered?. <i>Alimentary Pharmacology and Therapeutics</i> , 2010 , 31, 922-3; author reply 923-4	6.1	5
75	Renzapride in IBS: is efficacy in the eye of the beholder?. <i>Alimentary Pharmacology and Therapeutics</i> , 2010 , 32, 113-4; author reply 114-5	6.1	2
74	Systematic review: prognostic tests of paracetamol-induced acute liver failure. <i>Alimentary Pharmacology and Therapeutics</i> , 2010 , 31, 1064-76	6.1	57
73	Meta-analysis: factors affecting placebo response rate in the irritable bowel syndrome. <i>Alimentary Pharmacology and Therapeutics</i> , 2010 , 32, 144-58	6.1	149
72	Dyspepsia and irritable bowel syndrome: mutually exclusive conditions?. <i>Alimentary Pharmacology and Therapeutics</i> , 2010 , 32, 612-3; author reply 613	6.1	2

71	Reporting of relapse rates in a trial of mesalazine for ulcerative colitis. <i>Alimentary Pharmacology and Therapeutics</i> , 2010 , 32, 1205-6; author reply 1206-7	6.1	1
70	Infliximab rescue therapy in ulcerative colitis, and the effect on subsequent colectomy rates. <i>Alimentary Pharmacology and Therapeutics</i> , 2010 , 32, 1294-5	6.1	3
69	Costs of care for Crohn's disease following the introduction of infliximab: a single-centre UK experience. <i>Alimentary Pharmacology and Therapeutics</i> , 2010 , 32, 1357-63	6.1	28
68	Effect of oral zinc in hepatic encephalopathy remains unclear. <i>Alimentary Pharmacology and Therapeutics</i> , 2010 , 32, 1405-6; author reply 1406-7	6.1	3
67	Systematic review: granulocyte/monocyte adsorptive apheresis for ulcerative colitis. <i>Alimentary Pharmacology and Therapeutics</i> , 2010 , 32, 1297-306	6.1	37
66	Efficacy of azathioprine versus mesalazine in postoperative Crohn's disease. <i>Gut</i> , 2010 , 59, 1731-2	19.2	2
65	Errors in the conduct of systematic reviews of pharmacological interventions for irritable bowel syndrome. <i>American Journal of Gastroenterology</i> , 2010 , 105, 280-8	0.7	40
64	Low yield of colonoscopy in individuals with suspected irritable bowel syndrome?. <i>American Journal of Gastroenterology</i> , 2010 , 105, 2508-9	0.7	
63	Overlap among the functional gastrointestinal disorders. <i>American Journal of Gastroenterology</i> , 2010 , 105, 2512	0.7	3
62	What is the prevalence of clinically significant endoscopic findings in subjects with dyspepsia? Systematic review and meta-analysis. <i>Clinical Gastroenterology and Hepatology</i> , 2010 , 8, 830-7, 837.e1-2	6.9	121
61	Systematic review and meta-analysis of the prevalence of irritable bowel syndrome in individuals with dyspepsia. <i>Clinical Gastroenterology and Hepatology</i> , 2010 , 8, 401-9	6.9	134
60	The efficacy of probiotics in the treatment of irritable bowel syndrome: a systematic review. <i>Gut</i> , 2010 , 59, 325-32	19.2	472
59	The American College of Gastroenterology irritable bowel syndrome monograph: translating systematic review data to clinical practice. <i>Gastroenterology</i> , 2010 , 138, 789-91; author reply 791-2	13.3	6
58	Prevalence of uninvestigated dyspepsia 8 years after a large waterborne outbreak of bacterial dysentery: a cohort study. <i>Gastroenterology</i> , 2010 , 138, 1727-36; quiz e12	13.3	60
57	Disease activity and venous thromboembolism in inflammatory bowel disease. <i>Lancet, The</i> , 2010 , 375, 1690; author reply 1690-1	40	
56	"Power" of selective serotonin reuptake inhibitors in irritable bowel syndrome. <i>Clinical Gastroenterology and Hepatology</i> , 2010 , 8, 313-4; author reply 314	6.9	2
55	PTU-055 Safety and tolerability of combination therapy for chronic hepatitis C: the Leeds experience. <i>Gut</i> , 2010 , 59, A71.1-A71	19.2	
54	Epidemiology of <i>Helicobacter pylori</i> infection and public health implications. <i>Helicobacter</i> , 2010 , 15 Suppl 1, 1-6	4.9	97

53	Is the benefit of granulocyte monocyte adsorptive apheresis in ulcerative colitis overstated? <i>Digestive Diseases and Sciences</i> , 2010 , 55, 1803; author reply 1803-4	4	3
52	Irritable bowel syndrome. <i>Clinical Evidence</i> , 2010 , 2010,		1
51	Efficacy of 5-HT3 antagonists and 5-HT4 agonists in irritable bowel syndrome: systematic review and meta-analysis. <i>American Journal of Gastroenterology</i> , 2009 , 104, 1831-43; quiz 1844	0.7	198
50	Yield of diagnostic tests for celiac disease in individuals with symptoms suggestive of irritable bowel syndrome: systematic review and meta-analysis. <i>Archives of Internal Medicine</i> , 2009 , 169, 651-8		155
49	Accelerated infliximab infusions are safe and well tolerated in patients with inflammatory bowel disease. <i>European Journal of Gastroenterology and Hepatology</i> , 2009 , 21, 71-5	2.2	32
48	Treatment of chronic gastro-oesophageal reflux disease. <i>BMJ, The</i> , 2009 , 339, b2481	5.9	2
47	Testing for Celiac Disease in Patients With Symptoms of Irritable Bowel SyndromeReply. <i>JAMA - Journal of the American Medical Association</i> , 2009 , 301, 1126	27.4	1
46	Managing dyspepsia. <i>Current Gastroenterology Reports</i> , 2009 , 11, 288-94	5	8
45	10-biomarker algorithm to identify irritable bowel syndrome. <i>Alimentary Pharmacology and Therapeutics</i> , 2009 , 30, 95-6; author reply 96-7	6.1	4
44	Meta-analysis: yield of diagnostic tests for coeliac disease in dyspepsia. <i>Alimentary Pharmacology and Therapeutics</i> , 2009 , 30, 28-36	6.1	42
43	Generalized anxiety disorder and irritable bowel syndrome. <i>Alimentary Pharmacology and Therapeutics</i> , 2009 , 30, 1087-8; author reply 1088-9	6.1	2
42	Small intestinal bacterial overgrowth in irritable bowel syndrome: systematic review and meta-analysis. <i>Clinical Gastroenterology and Hepatology</i> , 2009 , 7, 1279-86	6.9	260
41	Efficacy of antidepressants and psychological therapies in irritable bowel syndrome: systematic review and meta-analysis. <i>Gut</i> , 2009 , 58, 367-78	19.2	404
40	Efficacy of probiotics in irritable bowel syndrome: a meta-analysis of randomized, controlled trials. <i>Diseases of the Colon and Rectum</i> , 2009 , 52, 1805; author reply 1806	3.1	6
39	Redundant data in the meta-analysis on <i>Helicobacter pylori</i> eradication. <i>Annals of Internal Medicine</i> , 2009 , 151, 513; author reply 513-4	8	16
38	Does <i>Helicobacter pylori</i> really cause duodenal ulcers? Yes. <i>BMJ, The</i> , 2009 , 339, b2784	5.9	4
37	<i>Helicobacter pylori</i> infection. <i>Clinical Evidence</i> , 2009 , 2009,		2
36	Should we step-up or step-down in the treatment of new-onset dyspepsia in primary care? 2009 , 119, 391-6		2

35	Management of irritable bowel syndrome. <i>Minerva Gastroenterologica E Dietologica</i> , 2009 , 55, 273-87	1.6	4
34	Meta-analysis: Helicobacter pylori 'test and treat' compared with empirical acid suppression for managing dyspepsia. <i>Alimentary Pharmacology and Therapeutics</i> , 2008 , 28, 534-44	6.1	37
33	Fluctuation of gastrointestinal symptoms in the community: a 10-year longitudinal follow-up study. <i>Alimentary Pharmacology and Therapeutics</i> , 2008 , 28, 1013-20	6.1	42
32	Helicobacter pylori test and treat versus proton pump inhibitor in initial management of dyspepsia in primary care: multicentre randomised controlled trial (MRC-CUBE trial). <i>BMJ, The</i> , 2008 , 336, 651-4	5.9	61
31	Diagnostic utility of alarm features for colorectal cancer: systematic review and meta-analysis. <i>Gut</i> , 2008 , 57, 1545-53	19.2	107
30	Effect of fibre, antispasmodics, and peppermint oil in the treatment of irritable bowel syndrome: systematic review and meta-analysis. <i>BMJ, The</i> , 2008 , 337, a2313	5.9	368
29	Current guidelines for dyspepsia management. <i>Digestive Diseases</i> , 2008 , 26, 225-30	3.2	29
28	Irritable bowel syndrome: a 10-yr natural history of symptoms and factors that influence consultation behavior. <i>American Journal of Gastroenterology</i> , 2008 , 103, 1229-39; quiz 1240	0.7	150
27	Balancing the risk of chronic gastrointestinal bleeding and thromboembolic events in a patient with a metallic aortic valve. <i>Clinical Medicine</i> , 2008 , 8, 461-2	1.9	
26	Will the history and physical examination help establish that irritable bowel syndrome is causing this patient's lower gastrointestinal tract symptoms?. <i>JAMA - Journal of the American Medical Association</i> , 2008 , 300, 1793-805	27.4	68
25	Adverse events with bismuth salts for Helicobacter pylori eradication: systematic review and meta-analysis. <i>World Journal of Gastroenterology</i> , 2008 , 14, 7361-70	5.6	85
24	The Efficacy of Probiotics in the Therapy of Irritable Bowel Syndrome (IBS). <i>American Journal of Gastroenterology</i> , 2008 , 103, S481	0.7	4
23	Electronic Clinical Challenges and Images in GI. <i>Gastroenterology</i> , 2007 , 133, e3-e4	13.3	
22	Mycophenolate mofetil therapy for refractory inflammatory bowel disease. <i>Inflammatory Bowel Diseases</i> , 2007 , 13, 1488-92	4.5	28
21	The Short-Form Leeds Dyspepsia Questionnaire validation study. <i>Alimentary Pharmacology and Therapeutics</i> , 2007 , 25, 477-86	6.1	57
20	Clinical trial: knowledge of negative Helicobacter pylori status reduces subsequent dyspepsia-related resource use. <i>Alimentary Pharmacology and Therapeutics</i> , 2007 , 26, 1267-75	6.1	7
19	Who consults with dyspepsia? Results from a longitudinal 10-yr follow-up study. <i>American Journal of Gastroenterology</i> , 2007 , 102, 957-65	0.7	58
18	Initial poor quality of life and new onset of dyspepsia: results from a longitudinal 10-year follow-up study. <i>Gut</i> , 2007 , 56, 321-7	19.2	80

17	Effect of sibling number in the household and birth order on prevalence of <i>Helicobacter pylori</i> : a cross-sectional study. <i>International Journal of Epidemiology</i> , 2007 , 36, 1327-33	7.8	26
16	Cough in the community: a cross sectional survey and the relationship to gastrointestinal symptoms. <i>Thorax</i> , 2006 , 61, 975-9	7.3	156
15	Eradication therapy for peptic ulcer disease in <i>Helicobacter pylori</i> positive patients. <i>Cochrane Database of Systematic Reviews</i> , 2006 , CD003840		69
14	<i>Helicobacter pylori</i> "test and treat" or endoscopy for managing dyspepsia: an individual patient data meta-analysis. <i>Gastroenterology</i> , 2005 , 128, 1838-44	13.3	85
13	Image of the month. Autoimmune pancreatitis. <i>Gastroenterology</i> , 2005 , 129, 785, 1141	13.3	1
12	A community screening program for <i>Helicobacter pylori</i> saves money: 10-year follow-up of a randomized controlled trial. <i>Gastroenterology</i> , 2005 , 129, 1910-7	13.3	48
11	Initial management strategies for dyspepsia. <i>Cochrane Database of Systematic Reviews</i> , 2005 , CD001961		56
10	Gastro-oesophageal reflux is more prevalent in Western dyspeptics: a prospective comparison of British and South-East Asian patients with dyspepsia. <i>Alimentary Pharmacology and Therapeutics</i> , 2005 , 21, 1483-90	6.1	71
9	Ethnicity, gender, and socioeconomic status as risk factors for esophagitis and Barrett's esophagus. <i>American Journal of Epidemiology</i> , 2005 , 162, 454-60	3.8	128
8	Eradication therapy in <i>Helicobacter pylori</i> positive peptic ulcer disease: systematic review and economic analysis. <i>American Journal of Gastroenterology</i> , 2004 , 99, 1833-55	0.7	126
7	Mycophenolate mofetil in refractory inflammatory bowel disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2003 , 17, 1365-9	6.1	20
6	Recent developments in gastroenterology. <i>BMJ, The</i> , 2002 , 325, 1399-402	5.9	12
5	Hemobiliary from arterial pseudoaneurysm. <i>Gastroenterology</i> , 2002 , 122, 1720, 2098	13.3	1
4	Immunologic distribution of an organic anion transport protein in rat liver and kidney. <i>American Journal of Physiology - Renal Physiology</i> , 1996 , 271, G231-8	5.1	61
3	Dyspepsia: Ulcer and Non-Ulcer/Bloating and Early Satiety/Belching and Rumination22-25		
2	Definitions and Classifications of Irritable Bowel Syndrome1-21		2
1	Effect of gastro-esophageal reflux symptoms on the risk of Barrett's esophagus: A systematic review and meta-analysis. <i>Journal of Gastroenterology and Hepatology (Australia)</i> ,	4	1